Trials / Completed
CompletedNCT01910597
Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Prince of Songkla University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Soluble Beta-Glucan (SBG) is a compound prepared from commercial active dry Baker's yeast which is then proceeded through a multi-step laboratory processes invented by Prof. Rapepun Wititsuwannakul, Faculty of Science, Prince of Songkla University, Thailand. Based upon pre-clinical data, SBG has been shown to inhibit angiogenesis and probably enhance immune function, leading to shrinkage of tumor size in athymic nude mice injected by hepatocellular carcinoma cells (HepG2) and cervical cancer cells. Therefore, the investigators expect to see the safety and anti-cancer property of SBG in patients with advanced cancer whom no available therapy can be offered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SBG |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2016-04-20
- Completion
- 2016-04-20
- First posted
- 2013-07-29
- Last updated
- 2021-10-11
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT01910597. Inclusion in this directory is not an endorsement.